Changchun BCHT Biotechnology Co., Ltd. (SHA: 688276), based in China, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its freeze-dried human rabies vaccine, developed using human diploid/MRC-5 cells.
This innovative vaccine utilizes human diploid cells, which are widely recognized in international vaccine production and derived from healthy human embryonic lung tissue. The formulation is free from residual heterologous cells, minimizing the risk of introducing foreign proteins and DNA. It boasts strong immunogenicity, a rapid onset of action, excellent safety profile, and prolonged immune duration. This vaccine is particularly well-suited for individuals with allergies, the elderly, and children with compromised immune systems.- Flcube.com
